Menu

Events

"Commercialization initiatives of NIH and partnership between NIH and Japanese companies (Case of Rakuten Medical Inc.)"

  • twitter
  • Facebook
  • LINE

National Institutes of Health (NIH) and LINK-J are pleased to co-host a webinar for the first time.
Although the NIH is known as the largest basic science research organization in the world, it is not widely known that the NIH is also actively involved in the commercialization of technology in collaboration with private companies. Dr. Michael L. Salgaller, Supervisor of Invention Development and Marketing Unit of NIH, will first talk about how NIH specifically collaborates with public and private companies and what benefits are provided to the collaborators.
As an example of collaboration, Dr. Miguel Garcia-Guzman, Ph.D., Founder and CSO of Rakuten Medical Inc., will explain the merits of collaborating with NIH and the photoimmunotherapy that they are working on.
We hope that this webinar will provide you with an opportunity to learn more about the NIH's activities, and it will help to create new collaborations between you and the NIH.

- Simultaneous interpretation will be provided.
- English subtitles will be available (you can choose to turn them on or off).
- Please note that the subtitles are based on commercially available applications and that LINK-J and NIH are not responsible for any errors or omissions in the translation.

- How to use captions: Managing and viewing closed captioning


Date and Time

May 19, 2021 Friday 9:00-10:15am (JST)

Venue

Online(ZOOM)


Registration

(Opens an external site)

Registration Fee

Free
Click ”Registration” to open an external site, and click “GET TICKET” on the right bar to sign up for the webinar.

How to participate

This event will be broadcasted on Zoom webinar. Please make a registration through Peatix.
You can join the webinar from "Watch" in the Peatix page on the webinar day.

Program

Time Agenda
9:00-9:05AM(JST)
5:00-5:05PM(PDT)
8:00-8:05PM(EDT)
Welcome - Akihiko Soyama, LINK-J
Remarks - Dr. Michael L. Salgaller, Ph.D., Supervisor, Invention Development and Marketing Unit (IDMU), Technology Transfer Center | National Cancer Institute | National Institutes of Health
9:05-9:30AM(JST)
5:05-5:30PM(PDT)
8:05-8:30PM(EDT)
Presentation - Dr. Michael L. Salgaller
9:30-9:35AM(JST)
5:30-5:35PM(PDT)
8:30-8:35PM(EDT)
Q&A - Dr. Michael L. Salgaller
9:35-10:00AM(JST)
5:35-6:00PM(PDT)
8:35-9:00PM(EDT)
Presentation - Dr. Miguel Garcia-Guzman, Ph.D., Founder and CSO of Rakuten Medical Inc.
10:00-10:14AM(JST)
6:00-6:14PM(PDT)
9:00-9:14PM(EDT)
Q&A and Discussion - moderated by Drs. Salgaller and Guzman
10:14-10:15AM(JST)
6:14-6:15PM(PDT)
9:14-9:15PM(EDT)
Closing Remarks - A. Soyama

Biography

michael%20%28002%29.JPGDr. Michael L. Salgaller, Ph.D., Supervisor, Invention Development and Marketing Unit (IDMU), Technology Transfer Center | National Cancer Institute | National Institutes of Health

Dr. Michael Salgaller leads the Invention Development and Marketing Unit (IDMU) within the National Cancer Institute’s Technology Transfer Center, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support licensing and technology development partnerships. The IDMU serves in a business development role to foster licensing and collaborative activity between buy-side stakeholders and the NIH. He is a long-time industry executive who held various positions in boutique professional service and early-stage biotechnology firms – as well as several years in government affairs and on the investment team of a venture capital firm dedicated to the life sciences. He is the author of “Biotechnology Entrepreneurship,” and teaches an entrepreneurship class at NIH. He is on the Board of Canines-N-Kids, a foundation supporting cooperation between researchers in pediatric and veterinary oncology. He has written over 100 articles, presentations, and book chapters. Dr. Salgaller received his PhD in Pathology from The Ohio State University.

miguelggg.pngDr. Miguel Garcia-Guzman, Ph.D., Founder and CSO of Rakuten Medical Inc.

Dr. Miguel Garcia-Guzman, Ph.D., Vice Chairman & CSO. He founded Aspyrian Therapeutics in 2011, which became Rakuten Medical in 2019, to develop Photoimmunotherapy based on the IlluminoxTM platform as a novel branch of cancer treatments. Dr. Garcia-Guzman brings more than 25 years of R&D experience in the biopharmaceutical industry and academic institutions. Before founding Rakuten Medical, Dr. García-Guzman worked at Vertex Pharmaceuticals and other biopharmaceutical companies where he led R&D programs in various therapeutic areas. Previously to joining the biopharmaceutical industry Dr. García-Guzman conducted research at academic centers in the USA, Germany, and Spain, where he obtained a PhD in Pharmacology and Molecular Biology.

Participation fee

Free Click ”Registration” to open an external site, and click “GET TICKET” on the right bar to sign up for the webinar.

Organizer

Host: LINK-J
Co-host: NIH

Contact

LINK-J Email: contact@link-j.org

pagetop